Pharmacological profile of roflumilast;Perfil farmacológico del roflumilast

Archivos de Bronconeumologia

Volumn 46, Issue SUPPL.10, 2010, Pages 19-24

  Cortijo Gimeno, Julio ^a,b   Sánchez, Esteban Morcillo ^a,b  

^a HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

Author keywords

(COPD); Anti emphysema drug; Anti remodeling agents; Antiinflammatory; Chronic obstructive pulmonary disease; Mucus regulation; Phosphodiesterase 4 (PDE4) inhibitor; Roflumilast

Indexed keywords

PHOSPHODIESTERASE IV; REACTIVE OXYGEN METABOLITE; ROFLUMILAST;

ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; CELL PROLIFERATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME INHIBITION; EPITHELIUM CELL; HUMAN; INFLAMMATORY CELL; LUNG BLOOD VESSEL; MUCUS SECRETION; NEUTROPHIL; PULMONARY ARTERY; PULMONARY HYPERTENSION; SMOOTH MUSCLE FIBER;

AIRWAY REMODELING; AMINOPYRIDINES; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BENZAMIDES; CELL DIVISION; CILIA; CYCLOPROPANES; DRUG EVALUATION, PRECLINICAL; FIBROBLASTS; HUMANS; HYPERTENSION, PULMONARY; MACROPHAGES; MICE; MOLECULAR STRUCTURE; MUCUS; MYOCYTES, SMOOTH MUSCLE; NEUTROPHILS; OXIDANTS; OXIDATIVE STRESS; PHOSPHODIESTERASE 4 INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMPHYSEMA; RATS; SMOKE; TOBACCO;

EID: 79851498664     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/S0300-2896(10)70052-1     Document Type: Article

References (54)

1. Amschler H. Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors. PCT Patent WO95/01338; 1995.
2. Hatzelmann A., Schudt C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 2001, 297:267-279.
3. Claveau D., Chen S.L., O'Keefe S., Zaller D.M., Styhler A., Liu S. Preferential inhibition of T helper1, but not T helper2, cytokines in vitro by L-826,141[4-[2-(3,4-Bisdiflurome thoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]3- methylpyridine-1-oxide], a potent and selective phosphodiesterase 4 inhibitor. J Pharmacol Exp Ther 2004, 310:752-760.
4. Bethke T.D., Bohmer G.M., Hermann R., Hauns B., Fux R., Morike K., et al. Dose-proportional intraindividual single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor. J Clin Pharmacol 2007, 47:26-36.
5. Hatzelmann A., Morcillo E.J., Lungarella G., Adnot S., Sanjar S., Beume R., et al. The preclinical pharmacology of roflumilast: A selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2010, 23:235-256.
6. Churg A., Cosio M., Wright J.L. Mechanisms of cigarette smoke-induced COPD: Insights from animal models. Am J Physiol Lung Cell Mol Physiol 2008, 294:L6 12-31.
7. Fox J.C., Fitzgerald M.F. The role of animal models in the pharmacological evaluation of emerging anti-inflammatory agents for the treatment of COPD. Curr Opin Pharmacol 2009, 9:231-242.
8. Martorana P.A., Lunghi B., Lucattelli M., De C.G., Beume R., Lungarella G. Effect of roflumilast on inflammatory cells in the lungs of cigarette smoke-exposed mice. BMC Pulm Med 2008, 8:17.
9. Shore S.A., Shapiro S.D. Asthma and COPD: animal models. Asthma and COPD, basic mechanisms and clinical management 2008, AcademicPress, Amsterdam, p. 99-109.
10. Wright J.L., Cosio M., Churg A. Animal models of chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol 2008, 295:L1-L15.
11. Fitzgerald M.F., Spicer D., McAulay A.E., Wollin L., Beume R. Roflumilast but not methylprednisolone inhibited cigarette smoke-induced pulmonary inflammation in Guinea pigs. Eur Respir J Suppl 2006, (Suppl 663):P3850.
12. Martorana P.A., Beume R., Lucattelli M., Wollin L., Lungarella G. Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke. Am J Respir Crit Care Med 2005, 172:848-853.
13. Weidenbach A., Braun C., Schwoebel F., Beume R., Marx D. Therapeutic effects of various PDE4 inhibitors on cigarette smoke-induced pulmonary neutrophilia in mice. Am J Respir Crit Care Med 2008, 178:A651.
14. Le Q.C., Guenon I., Gillon J.Y., Valenca S., Cayron-Elizondo V., Lagente V., et al. The selective MMP-12 inhibitor, AS111793 reduces airway inflammation in mice exposed to cigarette smoke. Br J Pharmacol 2008, 154:1206-1215.
15. Hardaker E.L., Freeman M.S., Dale N., Raza F., Mok J., Banner K.H., et al. Characterisation of a model that mimicks aspects of the hyper-inflammatory response observed during an acute exacerbation of COPD. Am J Respir Crit Care Med 2009, 179:A5351.
16. Cortijo J., Iranzo A., Milara X., Mata M., Cerdá-Nicolás M., Ruiz-Saurí A., et al. Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin-induced lung injury. Br J Pharmacol 2009, 156:534-544.
17. Sanz M.J., Cortijo J., Taha M.A., Cerdá-Nicolás M., Schatton E., Burgbacher B., et al. Roflumilast inhibits leukocyte-endothelial cell interactions, expression of adhesion molecules and microvascular permeability. Br J Pharmacol 2007, 152:481-492.
18. Tenor H., Burgbacher B., Schudt C., Hatzelmann A. Effects of roflumilast and other PDE4 inibitors on human CD8 p T-cell functions. Eur Respir J Suppl 2005, 26:S717.
19. Milara J., Cortijo J., Mata M., Donet E., Mauricio M., Morcillo E.J. The PDE4 inhibitor roflumilast N-oxide partly reversed TGFß1-induced changes in collagen I and E-cadherin expression in human airway epithelial cells. Eur Respir J Suppl 2008, (Suppl 639):P3648.
20. Sabatini F., Petecchia L., Boero S., Silvestri M., Klar J., Tenor H., et al. A phosphodiesterase 4 inhibitor, roflumilast N-oxide, inhibits human lung fibroblast functions in vitro. Pulm Pharmacol Ther 2010, 23:283-291.
21. Burgess J.K., Oliver B.G., Poniris M.H., Ge Q., Boustany S., Cox N., et al. A phosphodiesterase 4 inhibitor inhibits matrix protein deposition in airways in vitro. J Allergy Clin Immunol 2006, 118:649-657.
22. Fox J.C., Spicer D., Henning R., Meshi B., Shrad M.T., Hogg J.C. Efficacy of the PDE4 inhibitor, BAY 19-8004, in tobacco smoke models of COPD in the Guinea pig. Am J Respir Crit Care Med 2003, 167:A91.
23. Jones N.A., Boswell-Smith V., Lever R., Page C.P. The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro. Pulm Pharmacol Ther 2005, 18:93-101.
24. Muzaffar S., Shukla N., Angelini G.D., Jeremy J.Y. Roflumilast N-oxide inhibits NADPH oxidase expression and activity in human pulmonary artery smooth muscle cells. Proc Br Pharmacol Soc 2008, 6:027P.
25. Namkoong S., Kim C.K., Cho Y.L., Kim J.H., Lee H., Ha K.S., et al. Forskolin increases angiogenesis through the coordinated cross-talk of PKA-dependent VEGF expression and Epac-mediated PI3K/Akt/eNOS signaling. Cell Signal 2009, 21:906-915.
26. Araya J., Cambier S., Markovics J.A., Wolters P., Jablons D., Hill A. Squamous metaplasia amplifies pathologic epitheliale mesenchymal interactionsin COPD patients. J Clin Invest 2007, 117:3551-3562.
27. Borzone G., Moreno R., Urrea R., Meneses M., Oyarzun M., Lisboa C. Bleomycin-induced chronic lung damage does not resemble human idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2001, 163:1648-1653.
28. Chaudhary N.I., Schnapp A., Park J.E. Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. Am J Respir Crit Care Med 2006, 173:769-776.
29. Kohyama T., Liu X., Wen F.Q., Zhu Y.K., Wang H., Kim H.J. PDE4 inhibitors attenuate fibroblast chemotaxis and contraction of native collagen gels. Am J Respir Cell Mol Biol 2002, 26:694-701.
30. Kohyama T., Liu X., Wen F.Q., Kobayashi T., Fang Q., Abe S. Cytokines modulate cilomilast response in lung fibroblasts. Clin Immunol 2004, 111:297-302.
31. Chaouat A., Naeije R., Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J 2008, 32:1371-1385.
32. Izikki M., Raffestin B., Klar J., Hatzelmann A., Marx D., Tenor H., et al. Effects of roflumilast, a phosphodiesterase-4 inhibitor, on hypoxia- and monocrotaline-induced pulmonary hypertension in rats. J Pharmacol Exp Ther 2009, 330:54-62.
33. Schudt C., Winder S., Forderkunz S., Hatzelmann A., Ullrich V. Influence of selective phosphodiesterase inhibitors on human neutrophil functions and levels of cAMP and Cai. Naunyn Schmiedebergs Arch Pharmacol 1991, 344:682-690.
34. Hogg J.C., Chu F., Utokaparch S., Woods R., Elliott W.M., Buzatu L., et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004, 350:2645-2653.
35. Agusti A.G. COPD, a multicomponent disease: Implications for management. Respir Med 2005, 99:670-682.
36. Wohlsen A., Wollin L., Marx D., Beume R. Effect of roflumilast and other cAMP elevating agents on airway beat ciliary frequency in proximal and distal airways in rat precision cut lung slices. Fifth International Multidisciplinary Conference on Chronic Obstructive Pulmonary Disease (COPD5) 2006.
37. Milara J., Cortijo J., Armengot M., Banuls P., Gabarda E., Morcillo E. Effect of roflumilast, a PDE4 inhibitor on ciliary beat frequency in human nasal epithelial cells. Eur Respir J Suppl 2008, (Suppl 639):P3651.
38. Pedemonte N., Galietta L. Stimulation of CFTR-dependent chloride secretion by roflumilast. Eur Respir J Suppl 2008, (Suppl 644):P3672.
39. Mata M., Sarria B., Buenestado A., Cortijo J., Cerdá M., Morcillo E.J. Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells. Thorax 2005, 60:144-152.
40. Weidenbach A., Braun C., Schwoebel F., Beume R., Marx D. Steroid insensitivity in a shortterm model of cigarette smoke induced pulmonary inflammation in mice. Am J Respir Crit Care Med 2008, 177:A651.
41. Graat-Verboom L., Wouters E.F., Smeenk F.W., Van den Borne B.E., Lunde R., Spruit M.A. Current status of research on osteoporosis in COPD: A systematic review. Eur Respir J 2009, 34:209-218.
42. Yao W., Tian X.Y., Chen J., Setterberg R.B., Lundy M.W., Chmielzwski P., et al. Rolipram, a phosphodiesterase 4 inhibitor, prevented cancellous and cortical bone loss by inhibiting endosteal bone resorption and maintaining the elevated periosteal bone formation in adult ovariectomized rats. J Musculoskelet Neuronal Interact 2007, 7:119-130.
43. Chang J., Wang Z., Tang E., Fan Z., McCauley L., Franceschi R., et al. Inhibition of osteoblastic bone formation by nuclear factor-kappaB. Nat Med 2009, 15:682-689.
44. Hinkle R.T., Dolan E., Cody D.B., Bauer M.B., Isfort R.J. Phosphodiesterase 4 inhibition reduces skeletal muscle atrophy. Muscle Nerve 2005, 32:775-781.
45. O'Donnell J.M., Zhang H.T. Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4). Trends Pharmacol Sci 2004, 25:158-163.
46. Bolton C.E., Evans M., Ionescu A.A., Edwards S.M., Morris R.H., Dunseath G., et al. Insulin resistance and inflammation: A further systemic complication of COPD. COPD 2007, 4:121-126.
47. Tiengo A., Fadini G.P., Avogaro A. The metabolic syndrome, diabetes and lung dysfunction. Diabetes Metab 2008, 34:447-454.
48. Waddleton D., Wu W., Feng Y., Thompson C., Wu M., Zhou Y.P., et al. Phosphodiesterase 3 and 4 comprise the major cAMP metabolizing enzymes responsible for insulin secretion in INS-1 (832/13) cells and rat islets. Biochem Pharmacol 2008, 76:884-893.
49. Ong W.K., Gribble F.M., Reimann F., Lynch M.J., Houslay M.D., Baillie G.S., et al. The role of the PDE4D cAMP phosphodiesterase in the regulation of glucagon- like peptide- 1 release. Br J Pharmacol 2009, 157:633-644.
50. Zhang R., Maratos-Flier E., Flier J.S. Reduced adiposity and high-fat diet-induced adipose inflammation in mice deficient for phosphodiesterase 4B. Endocrinology 2009, 150:3076-3082.
51. Evers S, Fingerle J, Himber J, Gretarsdottir S, Gulcher J. The use of PDE4D in the screening for medicaments against atherosclerosis. PCT Patent WO2004/ 090157; 2004.
52. Keatings V.M., Jatakanon A., Worsdell Y.M., Barnes P.J. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997, 155:542-548.
53. Marwick J.A., Kirkham P.A., Stevenson C.S., Danahay H., Giddings J., Butler K. Cigarette smoke alters chromatine modelin gand induces proinflammatory genes inratlungs. Am J Respir Cell Mol Biol 2004, 31:633-642.
54. Marwick J.A., Caramori G., Stevenson C.S., Casolari P., Jazrawi E., Barnes P.J. Inhibition of PI3Kdelta restores glucocorticoid functionin smoking- induced airway inflammation in mice. Am J Respir Crit Care Med 2009, 179:542-548.